Possible montelukast-induced XXXX .

@entity1 @entity1183 @entity5419 @entity1353 @entity566 @entity341 @entity1425 @entity26 @entity682 @entity5774 @entity89 @entity113 @entity2221 @entity39970 @entity5203
PURPOSE: A possible case of montelukast-induced @entity113 is reported. SUMMARY: A 46-year-old @entity1 with a history of severe @entity566 , including @entity5419 , and @entity113 was evaluated at the @entity341 ( @entity341 ) for an acute episode of @entity113 . Upon arrival at the @entity341 , the @entity1 had severe @entity89 , @entity1183 , uncontrollable cheek lifting, swollen eyes, and a swollen protruding tongue and was unable to catch her breath. Her @entity1353 was apparent, and she was unable to talk and instead used hand and face gestures for affirmative and negative responses. The @entity1 was treated with 0.3 mg @entity1425 intramuscularly into the right thigh. After treatment, she had a temperature of 37 degrees C, a pulse of 90 beats/ min, a blood pressure value of 100/59 mm Hg, a respiratory rate of 16 breaths/min, and 100% @entity26 saturation on room air. After stabilization, she reported that her @entity566 had been adequately controlled with @entity39970 10 mg daily, montelukast 10 mg daily, and @entity2221 (unspecified). The @entity1 reported that since she started montelukast one month prior, she experienced three similar episodes, the first occurring five days after starting the drug. She mentioned being diagnosed and adequately treated these three times in the @entity341 for @entity113 . The @entity1 denied any changes in eating habits or in her medications except for starting @entity5203 . She was observed at the @entity341 for an hour and then discharged after stabilization on @entity5774 25 mg orally daily and @entity682 180 mg orally daily. Montelukast was discontinued. CONCLUSION: A @entity1 developed @entity113 four times during one month of treatment with montelukast.
